Tel Aviv-based Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, announced Monday that it successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA), and has received positive feedback on the clinical development plan for TRS02.
Follow Israel Hayom on Facebook and Twitter
Tarsier Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.
TRS02 is Tarsier's second formulation development, intended for use as slow-release intravitreal injections, targeting back-of-the-eye indications with an underlying inflammatory pathology, such as Posterior uveitis, Intermediate uveitis or Panuveitis, Diabetic Macular Edema, Non-Proliferative Diabetic Retinopathy, and others.
"We are grateful for the guidance provided by the FDA regarding the important aspects of the TRS02 program and excited to make progress in broadening our pipeline and seek cure for a range of blinding inflammatory ocular diseases," said Dr. Daphne Haim Langford, Chief Executive Officer at Tarsier.
